PREDICTION OF ANGIOGRAPHIC CHANGE IN NATIVE HUMAN CORONARY-ARTERIES AND AORTOCORONARY BYPASS GRAFTS - LIPID AND NONLIPID FACTORS
PREDICTION OF ANGIOGRAPHIC CHANGE IN NATIVE HUMAN CORONARY-ARTERIES AND AORTOCORONARY BYPASS GRAFTS - LIPID AND NONLIPID FACTORS
复制标题
DOI：
10.1161/01.cir.81.2.470
复制
发表时间：
1990-02-01
期刊：
影响因子：
37.8
通讯作者：
AZEN, SP
中科院分区：
文献类型：
--
作者：
BLANKENHORN, DH;ALAUPOVIC, P;AZEN, SP
在降胆固醇动脉粥样硬化研究中进行了一项组内风险因素分析，以预测血管造影的变化，该研究是一项在既往接受过冠状动脉搭桥手术的男性中进行的考来替泊加烟酸治疗的随机、安慰剂对照试验。治疗2年后，包括自体冠状动脉和旁路移植物在内的总体血管造影变化是终点。危险因素包括试验期间的临床指标、血脂、脂蛋白和载脂蛋白。单变量分析表明，先前在缺血性心脏病流行病学调查中观察到的风险因素disease.sbd.total胆固醇、LDL胆固醇、非HDL胆固醇、甘油三酯、载脂蛋白B和舒张压）对安慰剂治疗组有显著影响。单变量分析表明载脂蛋白C-III在药物治疗中具有显著作用，多变量分析表明预测全球冠状动脉进展概率的主要风险因素是palcebo治疗受试者的非HDL胆固醇和药物治疗受试者的高密度脂蛋白中载脂蛋白C-III的含量。药物治疗组和安慰剂治疗组的研究结果都指出了富含磷脂酰肌醇的脂蛋白在人类动脉粥样硬化的进展和消退中的重要作用。
A within-group risk factor analysis was conducted to predict angiographic change in the Cholesterol Lowering Atherosclerosis Study, a randomized, placebo-controlled trial of colestipol plus niacin therapy in men with previous coronary bypass surgery. Global angiographic change, including both native coronary arteries and bypass grafts after 2 treatment years, was the end point. Risk factors included on-trial clinical measures, plasma lipids, lipoproteins, and apolipoproteins. Univariate analysis indicated that risk factors previously observed by others in epidemiologic investigation of ischemic heart disease.sbd.total cholesterol, LDL cholesterol, non-HDL cholesterol, triglycerides, apolipoprotein B, and diastolic blood pressure.sbd.had significant effects in the placebo-treated group. Univariate analysis indicated significant effects of apolipoprotein C-III in drug- and Multivariate analysis indicated the predominant risk factor predicting the probability of global coronary progression was non-HDL cholesterol in palcebo-treated subjects and the content of apoliproprotein C-III in high density lipoproteins of drug-treated subjects. Both drug- and placebo-treated group findings point to an important role for triglyceride-rich lipoproteins in progression and regression of human atherosclerosis.